BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab

Update Il y a 4 ans
Reference: NCT02054481

Woman and Man

Extract

The overall purpose of this trial is to assess clinical efficacy and safety of different subcutaneous doses of BI 655066 in adult patients with chronic plaque psoriasis in order to select doses for further clinical trials.


Inclusion criteria

  • Psoriasis


Links